
|Articles|April 4, 2022
Stanley Capital-Backed Portfolio Company DSS Acquires MyMeds&Me
Advertisement
Stanley Capital Partners LLP (SCP) announced the acquisition of MyMeds&Me Limited (MMM) by its portfolio company Drug Safety and Pharmacovigilance Services Solutions (DSS). DSS is a global provider of pharmacovigilance services under the brand Bioclinica. The financial terms of the transaction are not being disclosed.
The combined, digital-first organization will provide a pharmacovigilance solution focused on the current and future requirements of the life sciences industry.
Read more about the acquisiton
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
Breaking the Efficacy Ceiling in IBD and Beyond
4
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
5



